Cellectar to participate in fireside chat at the h.c. wainwright bioconnect conference

Florham park, n.j., jan. 04, 2022 (globe newswire) -- cellectar biosciences, inc. (nasdaq: clrb), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of targeted drugs for the treatment of cancer, today announced jim caruso, president and ceo and jarrod longcor, cbo, will participate in a fireside chat at the h.c. wainwright bioconnect conference taking place virtually january 10-13, 2022.
CLRB Ratings Summary
CLRB Quant Ranking